Netherlands-based Bouwinvest Real Estate Investors has invested $60 million (€50 million) in life science office buildings across the United States via Blackstone’s BioMed Realty.
The investment, on behalf of its North America mandate, brings it closer to the $2 billion target that it set itself for 2022, up from the current $1.65 billion holding.
Bouwinvest said US life science real estate is “experiencing solid demand” which it says is being driven by growth in publicly and privately funded biomedical research.
BioMed’s assets are primarily located in the top-tier life science clusters in Boston, San Francisco, San Diego and Seattle. In these locations biomedical companies are located near to medical universities and hospitals and can thus tap into the local talent pool.
Bouwinvest’s director North American Investments Gijs Plantinga said the investment, “meets our real-value-for-life objectives by creating value in both financial and social terms.
“Our investment not only provides an attractive long-term return for Dutch pensioners, but also helps facilitate important medical research,” Plantinga said.
Bouwinvest opened a satellite office in New York in September 2020 to enable it to refine the search for investment opportunities. The firm said it sees other long-term opportunities in affordable housing, single-family rentals and logistics in North America, as well as in alternative segments such as life science offices and data centres.